(Q46646179)

English

The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.

scientific article published on 10 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Valeria Santini

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Stefania Ciolli

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Franco Leoni

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Cinzia Casini

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Carla Breschi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

0 references

publication date

10 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

141

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

814-819

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18410447%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Bortezomib and its role in the management of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Bortezomib: an effective agent in extramedullary disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07147.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46646179&oldid=1531121475"